Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
OssDsign AB is a pioneering medical technology company that specializes in designing innovative bone replacement products. Its primary focus is on providing effective solutions for cranial and facial reconstructive procedures. By leveraging advanced biomaterials and proprietary design technologies, OssDsign AB creates implants that contribute to natural healing processes, minimizing complications and delivering superior clinical outcomes. The company's offerings are particularly significant within the neurosurgery and maxillofacial surgery sectors, impacting the healthcare industry by enhancing patient care and recovery. With a commitment to improving patient quality of life through cutting-edge medical solutions, OssDsign AB plays an important role in advancing surgical applications and techniques. Its thoughtful integration of design, science, and medicine exemplifies its dedication to medical innovation.
kr 0.33
kr 0.00 (-1.20%)
Live · 11:04 PM · Twelve Data
The business is unprofitable at the operating level (-26.82% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 34.5% YoY with margins expanding 10.1pp.
Negative free cash flow of -kr 71M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 173M
▲ +34.5% YoY
Net Income (TTM)
-kr 48M
▼ -2.7% YoY
Op. Margin
-28.45%
▲ +10.1pp YoY
ROIC
-14.48%
▲ +2.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 65M
▼ -13.3% YoY
Op. Cash Flow (TTM)
-kr 56M
▼ -1.1% YoY
Net Debt
-kr 190M
Net Cash Position
Cash & Equiv.
kr 191M
3Y CAGR: +46.8%
Continue Research
OssDsign AB (OSSD.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, OssDsign AB scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
OssDsign AB scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -28.5% operating margin and a -14.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh OSSD.XSTO's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.